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A bit of Legalese upfront: The Disclaimer
• The content of this presentation is my own and does not 
necessarily reflect the views and/or policies of Foulston 
Siefkin LLP.  Foulston Siefkin LLP will not be bound by 
any of the comments or information contained in this 
presentation.  Regulations cited during this presentation 
should be read in full.   This is not intended as legal 
advice.  The choice of an attorney is an important one.  If 
you have questions or need further information please 
consult an attorney of your choosing.  
Navigating the FDA: Where do I begin?
Food and Drug Administration Office of the 
Commissioner
• CDER:  Center For Drug Evaluation and Research
• CVM:  Center for Veterinary Medicine
• CTP:  Center for Tobacco Products
• NCTR:  National Center for Toxiological Research
• ORA:  Office of Regulatory Affairs
• CFSAN:  Center for Food Safety and Applied Nutrition 
• CBER:  Center for Biologics Evaluation Research
• CDRH:  Center for Devices and Radiological Health
• For most device related inquires you will start with 
CDRH, but may also deal with CBER if your device 
deals with blood related products.
Medical Device Definition
• 21 CFR 201(h)
• If a product is labeled, promoted or used in a manner that meets the following 
definition of the Federal Food Drug & Cosmetic (FD&C) Act it will be regulated by 
the Food and Drug Administration (FDA) as a medical device and is subject to 
premarketing and postmarketing regulatory controls. 
• A device is:
• an instrument, apparatus, implement, machine, contrivance, implant, in vitro 
reagent, or other similar or related article, including a component part, or 
accessory which is:  
• recognized in the official National Formulary, or the United States 
Pharmacopoeia, or any supplement to them,
• intended for use in the diagnosis of disease or other conditions, or in 
the cure, mitigation, treatment, or prevention of disease, in man or 
other animals, or
• intended to affect the structure or any function of the body of man or 
other animals, and which does not achieve any of it's primary intended 
purposes through chemical action within or on the body of man or other 
animals and which is not dependent upon being metabolized for the 
achievement of any of its primary intended purposes.
In English Please
• Diagnosis, cure, mitigation, treatment or prevention of 
disease or condition
• Affects the structure or function of the body
• Does not achieve intended use through chemical action
• Is not metabolized to achieve effect
Device Classifications
• Class I:  Low risk, general controls, exempt from 
premarket submissions
• Crutches, band aids (excluding those intended to 
speed up healing)
• Class II:  Higher risk, more complex, premarket 
notification, 10% require clinical data
• Wheel chairs, tampons
• Class III:  Highest risk, life-supporting/sustaining, 
premarket approval (PMA) with animal/clinical data. 
• Heart valves, lap bands
General Controls
• General Controls:
• These are certain FDA statutory 
provisions designed to control the safety 
of marketed drugs and devices.  These 
include provisions on adulteration, 
misbranding, banned devices, good 
manufacturing practices (GMP), 
notification and record keeping, and 
other sections of the FDA Act found in 
21 CFR 360(c) and 513.  
Devices vs. Drugs vs. Biologics
• I often hear the question:  “How do I know if I have a 
drug, device, or something else?”
• Answer:
• Depends
• On the nature of the device industry
• Statutory distinctions
• Regulatory distinctions & similarities
• Research distinctions & similarities
Nature of the Device Industry
• Entrepreneurial firms common
• 93% have fewer than 100 employees
• Mostly venture capitalized
• Diverse and specialized products
• Device “developer” often involved
• Engineer driven
• Minimal clinical trials experience. 
• Shelf life of an average medical 
device is 18 months.
• Quick rate of change in industry.
• Devices on the market are 
quickly replaced by newer 
versions.
•Very important to work with a 
good patent attorney. 
Statutory Distinctions
• Devices lack market exclusivity provisions
• Waxman-Hatch (drugs)
• Orphan drug (drug/biologics)
• CMS allows for payment for unapproved devices under 
clinical study whereas drugs generally are not 
reimbursable. 
• Differences in standards approval
• “Substantial” adequate and well controlled trials for 
drugs
• “Reasonable” valid scientific evidence for a device. 
• Devices must down regulate
• Focus at FDA is to reduce cost and time to market. 
510(k) Devices:  What is this? 
• Not a form.  Rather it is a section in Code of Federal 
Regulations. 
• A medical device that is substantially equivalent to a 
device that was or is being legally marketed is 
covered by section 510(k) of the FD &C Act.
• The legally marketed device is referred to as a 
predicate device.
• A Sponsor planning to market a substantially 
equivalent device must submit notification to the 
FDA 90 DAYS IN ADVANCE of placing the device 
on the market. 
I’m in my 90 days, now what?
• No news is good news.  
• If after 90 days you haven’t heard anything from 
the FDA you are cleared to begin marketing your 
product.
• Post-marketing requirements
• Device pre-emption status for PMA cleared 
devices.
• Means that most state tort law claims for 
product liability cannot be brought. 
• Result of Riegel v. Medtronic
FDA’s Focus in 2010 for Devices
• Community Hospitals
• Institutional Review Boards
• Emergency Use of Devices
• Informed consent issues with 
devices
As a Device Sponsor
• Know the regulations or hire someone who 
does.  Critical!!!
• Select qualified investigators for PMA trials 
or 510(k)’s requiring clinical data.
• Obtain feedback on protocol requirements
• Provide adequate training UP FRONT.
• Ensure adequate monitoring of the trial
• Bring investigators into compliance. 
Don’t be afraid to ask for 
help. 
